Zacks Research Has Negative Estimate for CRL Q1 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Research analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for Charles River Laboratories International in a research report issued on Wednesday, March 12th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $2.08 per share for the quarter, down from their prior forecast of $3.10. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q2 2025 earnings at $2.38 EPS, Q3 2025 earnings at $2.51 EPS, Q4 2025 earnings at $2.58 EPS, FY2025 earnings at $9.55 EPS, Q1 2026 earnings at $2.46 EPS, Q2 2026 earnings at $2.66 EPS, Q3 2026 earnings at $2.71 EPS, Q4 2026 earnings at $2.78 EPS and FY2026 earnings at $10.60 EPS.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.46 earnings per share.

A number of other equities research analysts also recently weighed in on the company. JPMorgan Chase & Co. reduced their target price on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. UBS Group reiterated a “neutral” rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research report on Monday, November 18th. Barclays lowered their target price on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. Finally, William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $198.36.

Charles River Laboratories International Trading Up 2.3 %

Shares of CRL stock opened at $175.02 on Monday. The stock’s fifty day moving average price is $167.46 and its two-hundred day moving average price is $184.33. The company has a market cap of $8.95 billion, a PE ratio of 1,166.77, a P/E/G ratio of 4.54 and a beta of 1.45. Charles River Laboratories International has a fifty-two week low of $150.79 and a fifty-two week high of $274.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Hedge Funds Weigh In On Charles River Laboratories International

A number of hedge funds have recently added to or reduced their stakes in the stock. Empirical Finance LLC boosted its stake in Charles River Laboratories International by 4.2% during the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock valued at $258,000 after purchasing an additional 53 shares during the last quarter. Fiduciary Financial Group LLC lifted its position in shares of Charles River Laboratories International by 3.9% during the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after buying an additional 63 shares in the last quarter. Pinnacle Bancorp Inc. lifted its position in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares in the last quarter. M&T Bank Corp lifted its position in shares of Charles River Laboratories International by 3.4% during the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock worth $394,000 after buying an additional 66 shares in the last quarter. Finally, Cornerstone Investment Partners LLC lifted its position in shares of Charles River Laboratories International by 3.7% during the 4th quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company’s stock worth $358,000 after buying an additional 69 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Activity

In related news, COO Birgit Girshick purchased 1,514 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).